Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EBV-specific cytotoxic T lymphocyte therapy in chemotherapy-responding EBV-positive NK/T cell lymphoma
KCT0001271Phase 2Completed
- Sponsor
- Seoul St. Mary's Hospital
- Start
- Jul 2007
- Modality
- Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of Epstein-Barr virus specific cytotoxic T lymphocytes in Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL), sponsored by Seoul St. Mary's Hospital. Started Jul 2007; status: completed.
02
Drugs
Epstein-Barr virus specific cytotoxic T lymphocytes
03
Conditions
Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL)
Beyond the preview
Go deeper on KCT0001271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0001271.